Natco Pharma Ltd on Thursday said it has received approval from the US health regulator for its generic version of Everolimus tablets for oral suspension indicated for patients with tuberous ...

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam launch ...

under its brand Sovaldi. On 11 March 2015, Natco Pharma announced that it is the first company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India).

Drugmaker Natco Pharma on Tuesday said it intends to launch its generic version of spinal muscular atrophy drug Risdiplam only after and subject to successful clarity from the Appellate Bench of ...

Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...

A two-judge bench of Delhi High Court on Wednesday refrained Natco Pharma from launching the generic version of Swiss drugmaker Roche Pharma's patented drug Risdiplam until the hearing on April 2.

The Delhi High Court has denied an injunction request from Swiss pharma major La Hoffman Roche on March 25, in an alleged patent infringement case against Natco Pharma, potentially opening the ...

The Delhi High Court on Monday refused to allow a lawsuit filed by Swiss pharmaceutical company Roche that sought to restrain Indian drug maker Natco Pharma from manufacturing Risdiplam ...